文献速递肝病消化道肿瘤与早癌

STARD1通过线粒体替代途径维持胆汁酸生成促进NASH相关HCC

STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
PubMed 文献 · J Hepatol · 2021-01-27

该研究分析人NASH相关HCC标本及两种NASH驱动HCC小鼠模型,发现STARD1表达升高和胆汁酸池增大;STARD1过表达增加肝肿瘤数量,而肝细胞特异性缺失减少肿瘤负荷,其机制是经线粒体替代途径生成初级胆汁酸,刺激肿瘤起始干细胞自我更新、干性和炎症。

要点

  • NASH相关HCC患者肝脏STARD1表达增加且胆汁酸池增大
  • STARD1过表达增加肝肿瘤数量,肝细胞特异性缺失减少肿瘤负荷
  • STARD1经线粒体替代途径生成的胆汁酸刺激TICs干性与炎症

核心结论

  • STARD1通过维持线粒体替代途径生成初级胆汁酸促进NASH驱动HCC,产物作用于TICs刺激自我更新、干性和炎症。

研究设计与样本

  • 分析人NASH相关HCC标本中STARD1表达,并使用MUP-uPA小鼠高脂高胆固醇饮食及WT小鼠DEN联合高脂高胆固醇饮食两种NASH驱动HCC模型。
  • 采用质谱分析胆汁酸和氧固醇分子种类,在肿瘤起始干细胞和原代小鼠肝细胞中研究NASH来源胆汁酸谱的效应。

主要发现

  • NASH相关HCC患者肝脏STARD1表达增加且胆汁酸池增大。
  • STARD1过表达小鼠肝肿瘤数量增加,而肝细胞特异性STARD1缺失的WT或MUP-uPA小鼠肿瘤负荷减少。
  • 上述变化与非结合初级胆汁酸β-鼠胆酸和胆酸及其牛磺酸结合物的水平一致。
  • 模拟该胆汁酸谱的混合物刺激TICs或PMHs中多能性、干性和炎症相关基因表达。

临床怎么用

  • STARD1及其依赖的线粒体胆汁酸合成途径可能成为NASH相关HCC的潜在干预靶点。

局限性

  • STARD1依赖胆汁酸合成途径对HCC的贡献此前未被探索,STARD1在该过程中的生理相关性尚不完全清楚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Besides their physiological role in bile formation and fat digestion, bile acids (BAs) synthesised from cholesterol in hepatocytes act as signalling molecules that modulate hepatocellular carcinoma (HCC). Trafficking of cholesterol to mitochondria through steroidogenic acute regulatory protein 1 (STARD1) is the rate-limiting step in the alternative pathway of BA generation, the physiological relevance of which is not well understood. Moreover, the specific contribution of the STARD1-dependent BA synthesis pathway to HCC has not been previously explored. METHODS: STARD1 expression was analyzed in a cohort of human non-alcoholic steatohepatitis (NASH)-derived HCC specimens. Experimental NASH-driven HCC models included MUP-uPA mice fed a high-fat high-cholesterol (HFHC) diet and diethylnitrosamine (DEN) treatment in wild-type (WT) mice fed a HFHC diet. Molecular species of BAs and oxysterols were analyzed by mass spectrometry. Effects of NASH-derived BA profiles were investigated in tumour-initiated stem-like cells (TICs) and primary mouse hepatocytes (PMHs). RESULTS: Patients with NASH-associated HCC exhibited increased hepatic expression of STARD1 and an enhanced BA pool. Using NASH-driven HCC models, STARD1 overexpression in WT mice increased liver tumour multiplicity, whereas hepatocyte-specific STARD1 deletion (Stard1ΔHep) in WT or MUP-uPA mice reduced tumour burden. These findings mirrored the levels of unconjugated primary BAs, β-muricholic acid and cholic acid, and their tauroconjugates in STARD1-overexpressing and Stard1ΔHep mice. Incubation of TICs or PMHs with a mix of BAs mimicking this profile stimulated expression of genes involved in pluripotency, stemness and inflammation. CONCLUSIONS: The study reveals a previously unrecognised role of STARD1 in HCC pathogenesis, wherein it promotes the synthesis of primary BAs through the mitochondrial pathway, the products of which act in TICs to stimulate self-renewal, stemness and inflammation. LAY SUMMARY: Effective therapy for hepatocellular carcinoma (HCC) is limited because of our incomplete understanding of its pathogenesis. The contribution of the alternative pathway of bile acid (BA) synthesis to HCC development is unknown. We uncover a key role for steroidogenic acute regulatory protein 1 (STARD1) in non-alcoholic steatohepatitis-driven HCC, wherein it stimulates the generation of BAs in the mitochondrial acidic pathway, the products of which stimulate hepatocyte pluripotency and self-renewal, as well as inflammation.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Conde de la Rosa L, Garcia-Ruiz C, Vallejo C, et al. STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway. J Hepatol. 2021. PMID: 33515644. doi:10.1016/j.jhep.2021.01.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。